Teva has agreed to bid up to $125 million for BioXcel Therapeutics' neuroscience assets, including marketed agitation treatment Igalmi (dexmedetomidine), as the struggling biotech enters Chapter 11 bankruptcy. Teva will serve as the stalking-horse bidder in a court-supervised auction for substantially all of BioXcel's assets. Under the agreement, Teva would pay $57.5 million upfront for worldwide rights to the assets, with up to another $67.5 million in contingent payments. The latter includes

Financing supports advancement of AHB-137 toward potential commercialization, including its Phase 3 registrational program and commercialization readiness Proceeds will also accelerate AHB-171 and next-generation combination approaches designed to advance functional cure for chronic hepatitis B Series C brings AusperBio's total capital raised to $360 million since 2024 Aug. 27, 2026 -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively "AusperBio" or the "Company"), a n

ProFound Therapeutics has received up to $35 million in backing from the Gates Foundation, including an initial $20 million, to use its proteomics and AI platform to identify drug targets and biomarkers for preeclampsia and eclampsia. The Flagship Pioneering-founded biotech will analyse proteins found in the placenta and serum of women with the pregnancy complications. "The expanded proteome represents a vast and largely untapped resource for identifying novel protein drugs, drug targets," said

Designation supports the global development of RTX-117 and may provide potential future access to a transferable Priority Review Voucher, subject to approval and applicable requirements Aug. 26, 2026 -- ReviR Therapeutics, a clinical-stage biotechnology company advancing small-molecule therapies through the integration of artificial intelligence and RNA biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to RTX-117, the

SK Biopharmaceuticals has strengthened its epilepsy offering by paying $350 million upfront to help speed Biohaven’s Kv7 ion channel activator on its way to market. Biohaven is currently evaluating the daily oral therapy, called opakalim or BHV-7000, in a phase 2/3 study of patients with focal epilepsy. A topline readout is expected later this year. Rather than wait for the results, SK has agreed to hand over the upfront cash—along with another $50 million next year—for the worldwide license t

The first patient has been dosed in the TROPION-Urothelial04 phase 3 trial evaluating Datroway® (datopotamab deruxtecan) plus rilvegostomig or Datroway monotherapy versus current standard of care (durvalumab monotherapy or nivolumab monotherapy or enfortumab vedotin plus pembrolizumab) as an adjuvant treatment (after surgery) in patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection with or without prior neoadjuvant therapy. Datrow

The capital raise supports ongoing Phase 2b/3 clinical trial for prevention of bronchopulmonary dysplasia and associated CMC and analytical activities Approximately 94% of existing investors participated in the Series E-2 round Interim analysis completing the Phase 2b portion of the trial expected by the end of Q2 2027 Aug. 25, 2026 -- Airway Therapeutics, Inc., a late-stage clinical biopharmaceutical company developing novel biologic therapies for respiratory, inflammatory, and infectious dise

Shape Memory Medical Inc., developer of proprietary shape memory polymer technology for endovascular embolization, today announced the closing of a $10 million convertible note financing led by new investor August Global Partners (AGP), joined by fellow new investor Taiwania Capital. The financing provides capital to support continued clinical development of the company’s aortic portfolio, including patient follow-up and data collection in the AAA-SHAPE Pivotal Trial, and advancement of the FLA

COVID-19 remains a public health challenge, particularly among older adults and high-risk populations1 Novavax's partners are ready to bring its protein-based, non-mRNA vaccine with a favorable tolerability profile to global markets, providing an important option for healthcare providers and patients Aug. 28, 2026 -- Novavax, Inc.'s (Nasdaq: NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major ma

Spyre Therapeutics' stock was down about 14% Wednesday after a topline readout for one of its experimental TL1A antibodies underwhelmed in a Phase II rheumatoid arthritis (RA) study. While SPY072 showed activity, it failed to meet the company's internal efficacy bar for moving it forward as a stand-alone therapy. The candidate is being evaluated in the SKYWAY-RD basket trial across several rheumatic diseases, with separate sub-studies in RA, psoriatic arthritis (PsA) and axial spondyloarthritis